The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells

The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma cells were used. Cell viability, the percentage of...

Full description

Saved in:
Bibliographic Details
Main Authors: Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee
Format: Article
Language:English
Published: SAGE Publishing 2017-10-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317722068
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850055833375735808
author Si Hyoung Kim
Jun Goo Kang
Chul Sik Kim
Sung-Hee Ihm
Moon Gi Choi
Hyung Joon Yoo
Seong Jin Lee
author_facet Si Hyoung Kim
Jun Goo Kang
Chul Sik Kim
Sung-Hee Ihm
Moon Gi Choi
Hyung Joon Yoo
Seong Jin Lee
author_sort Si Hyoung Kim
collection DOAJ
description The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma cells were used. Cell viability, the percentage of viable cells, cytotoxic activity, the percentage of apoptotic cells, and mitochondrial membrane potential were measured. To evaluate the combined effect of gemigliptin with AUY922, the interactions were estimated by calculating combination index. Gemigliptin led to cell death in conjunction with overexpression of the phosphorylated protein levels of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase. In gemigliptin-treated cells, wortmannin augmented cell death, whereas AZD6244 and compound C did not affect cell survival. Wortmannin decreased phosphorylated adenosine monophosphate–activated protein kinase protein levels, and AZD6244 increased phosphorylated Akt protein levels. Meanwhile, cotreatment of both gemigliptin and AUY922, compared with treatment of AUY922 alone, potentiated cell death. All the combination index values were lower than 1.0, suggesting synergistic cytotoxicity of gemigliptin with AUY922. In treatment of both gemigliptin and AUY922, compared with AUY922 alone, the protein levels of total and phosphorylated Akt, phosphorylated extracellular signal–regulated kinase 1/2, and phosphorylated adenosine monophosphate–activated protein kinase increased without alteration in those of total extracellular signal–regulated kinase 1/2 and total adenosine monophosphate–activated protein kinase. The percentage of apoptotic cells increased. The protein levels of Bax and cleaved poly (ADP-ribose) polymerase increased, whereas Bcl2 protein levels were unchanged, resulting in increment of Bax/Bcl2 ratio. Transfection of Bax small interfering RNA did not cause any variation in cell viability, the percentage of viable cells and cytotoxic activity. Our results demonstrate that gemigliptin exerts a cytotoxic activity with concomitant alterations in expression of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase in thyroid carcinoma cells. Furthermore, gemigliptin synergizes with AUY922 in induction of cytotoxicity via regulation of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase as well as involvement of Bcl2 family proteins in thyroid carcinoma cells.
format Article
id doaj-art-d00b5da5e0644833b5bb3a524bdaf310
institution DOAJ
issn 1423-0380
language English
publishDate 2017-10-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-d00b5da5e0644833b5bb3a524bdaf3102025-08-20T02:51:52ZengSAGE PublishingTumor Biology1423-03802017-10-013910.1177/1010428317722068The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cellsSi Hyoung KimJun Goo KangChul Sik KimSung-Hee IhmMoon Gi ChoiHyung Joon YooSeong Jin LeeThe effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma cells were used. Cell viability, the percentage of viable cells, cytotoxic activity, the percentage of apoptotic cells, and mitochondrial membrane potential were measured. To evaluate the combined effect of gemigliptin with AUY922, the interactions were estimated by calculating combination index. Gemigliptin led to cell death in conjunction with overexpression of the phosphorylated protein levels of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase. In gemigliptin-treated cells, wortmannin augmented cell death, whereas AZD6244 and compound C did not affect cell survival. Wortmannin decreased phosphorylated adenosine monophosphate–activated protein kinase protein levels, and AZD6244 increased phosphorylated Akt protein levels. Meanwhile, cotreatment of both gemigliptin and AUY922, compared with treatment of AUY922 alone, potentiated cell death. All the combination index values were lower than 1.0, suggesting synergistic cytotoxicity of gemigliptin with AUY922. In treatment of both gemigliptin and AUY922, compared with AUY922 alone, the protein levels of total and phosphorylated Akt, phosphorylated extracellular signal–regulated kinase 1/2, and phosphorylated adenosine monophosphate–activated protein kinase increased without alteration in those of total extracellular signal–regulated kinase 1/2 and total adenosine monophosphate–activated protein kinase. The percentage of apoptotic cells increased. The protein levels of Bax and cleaved poly (ADP-ribose) polymerase increased, whereas Bcl2 protein levels were unchanged, resulting in increment of Bax/Bcl2 ratio. Transfection of Bax small interfering RNA did not cause any variation in cell viability, the percentage of viable cells and cytotoxic activity. Our results demonstrate that gemigliptin exerts a cytotoxic activity with concomitant alterations in expression of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase in thyroid carcinoma cells. Furthermore, gemigliptin synergizes with AUY922 in induction of cytotoxicity via regulation of Akt, extracellular signal–regulated kinase 1/2, and adenosine monophosphate–activated protein kinase as well as involvement of Bcl2 family proteins in thyroid carcinoma cells.https://doi.org/10.1177/1010428317722068
spellingShingle Si Hyoung Kim
Jun Goo Kang
Chul Sik Kim
Sung-Hee Ihm
Moon Gi Choi
Hyung Joon Yoo
Seong Jin Lee
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
Tumor Biology
title The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
title_full The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
title_fullStr The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
title_full_unstemmed The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
title_short The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells
title_sort dipeptidyl peptidase iv inhibitor gemigliptin alone or in combination with nvp auy922 has a cytotoxic activity in thyroid carcinoma cells
url https://doi.org/10.1177/1010428317722068
work_keys_str_mv AT sihyoungkim thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT jungookang thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT chulsikkim thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT sungheeihm thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT moongichoi thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT hyungjoonyoo thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT seongjinlee thedipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT sihyoungkim dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT jungookang dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT chulsikkim dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT sungheeihm dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT moongichoi dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT hyungjoonyoo dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells
AT seongjinlee dipeptidylpeptidaseivinhibitorgemigliptinaloneorincombinationwithnvpauy922hasacytotoxicactivityinthyroidcarcinomacells